{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269624","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.762679+00:00","generated_at":"2026-05-16T23:59:04.834725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026","bullets":["Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.","Cash, equivalents and marketable securities $383.9M as of Sep 30, 2025; runway into 2028 after $150M private placement.","MZE782 Phase 1 positive: well-tolerated, dose-dependent urinary Phe and glutamine increase; eGFR dip observed.","MZE782 Phase 2 trials in PKU and CKD expected to initiate in 2026; MZE829 HORIZON topline data by Q1 2026.","Appointed Hervé Hoppenot as chairman and Misbah Tahir as CFO in Sep/Oct 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269624","json":"https://secwatch.observer/filing/0001193125-25-269624.json","markdown":"https://secwatch.observer/filing/0001193125-25-269624.md","text":"https://secwatch.observer/filing/0001193125-25-269624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/0001193125-25-269624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:59:04.834725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}